COMPANY PROFILE

RECOMBINETICS

Explore full profile

Recombinetics uses gene editing technology to develop solutions for various biomedical and agricultural applications

Eagan, United StatesFounded 2008Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About RECOMBINETICS

Recombinetics is a pioneering company in the field of gene editing technology, focusing on improving human health and agricultural productivity. The company operates in the biopharmaceutical and agricultural sectors, serving clients ranging from healthcare providers to agricultural producers. Recombinetics' business model revolves around the development and application of gene editing techniques to create advanced disease models for regenerative medicine and precision breeding solutions for livestock. By leveraging cutting-edge genetic science, the company aims to extend human lifespans, enhance the quality of life, and increase agricultural yields while reducing animal suffering. Revenue is generated through partnerships, licensing agreements, and direct sales of their innovative genetic solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2008
Headquarters: Eagan, United States
Employees: 17
Open positions: None listed
Dealroom signal: 66.2/100
Industry: Health
Sub-industry: BioTechnology, AgriTech
Sector: Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Synthetic Biology, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Aug 2018	$34M	$136M	Undisclosed	↗
SEED✓Equity / VC	Jan 2018	—	—	Undisclosed	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

RECOMBINETICS website traffic

Latest recorded traffic for RECOMBINETICS is 870 monthly website visits, down 13% over the last three months. RECOMBINETICS's team declined 15% over the past year.

Latest monthly visits870 3-month web change-13% 1-year team growth-15%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MBMission BioThe equipment for molecular biology	San Francisco, United States	Operational	84	$141M	$280M
SYSynthorxBiotechnology company using synthetic biology to synthesize solutions	San Diego, United States	Acquired
PTPoseida TherapeuticsPoseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics	San Diego, United States	Acquired
ITIntellia TherapeuticsA leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases	Cambridge, United States	Operational
ARArcherDXBiotechnology firm specializing in cancer research	Boulder, United States	Acquired
PDParadigm DiagnosticsPrivate molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry	Phoenix, United States	Acquired
ASApplied StemCellAdvance gene-editing and stem cell innovation for biomedical research and the biotechnology industry	Milpitas, United States	Acquired
GEGeospizaSoftware developer of Next Gen Sequencing DNA Genetic Analysis and LIMS	Seattle, United States	Acquired